🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Lacuna Pharma Pty Ltd” Clear

  1. A Phase 1 Open-Label Mass Balance clinical trial to Investigate the Absorption, Metabolism, and Excretion of Single Oral Administration of [14C]-TEV-56286 Following Multiple Oral Administrations of Nonlabeled TEV-56286 to Healthy Male Participants.

    Lacuna Pharma Pty Ltd

    Healthy participant

    phase 1 other active

    1 trial
  2. A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients with Newly Diagnosed Glioblastoma

    Lacuna Pharma Pty Ltd

    Glioblastoma multiforme (GBM)

    phase 1 other active

    1 trial
  3. A Phase 1 relative bioavailability study in 14 healthy adult participants investigating the Arvisol® tablets to see whether its pharmacokinetic properties are similar to the reference drug which is a marketed oral soliton cannabidiol, named Epidiolex® CBD oral solution.

    Lacuna Pharma Pty Ltd

    Healthy volunteers

    phase 1 other active

    1 trial
  4. A Phase 1, Dose-Escalating, Randomized, Placebo-Controlled, 4-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of COR-1167 in Healthy Subjects and Subjects with Chronic Heart Failure (CHF)

    Lacuna Pharma Pty Ltd

    Chronic heart failure

    phase 1 other active

    1 trial
  5. A Phase 1, Double-blind, Randomized, Three-arm, Parallel Group Study to Compare the Pharmacokinetics and Safety of a Single Subcutaneous Dose of PBP1502, EU-Humira®, and US-Humira® in Healthy Male and Female Subjects

    Lacuna Pharma Pty Ltd

    Healthy volunteers

    phase 1 other active

    1 trial
  6. A Phase 1, Open-Label, 2-Period, 2-Formulation, Within-Subject Crossover Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects Under Fasting Conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a pharmacokinetic and pharmacodynamic safety study in healthy subjects)

    phase 1 other active

    1 trial
  7. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pimozide after Multiple Dose Administration in Subjects with Rheumatoid Arthritis

    Lacuna Pharma Pty Ltd

    rheumatoid arthritis

    phase 1 other active

    1 trial
  8. A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911

    Lacuna Pharma Pty Ltd

    Immune Thrombocytopenia, Hematopoietic Syndrome of Acute Radiation Syndrome

    phase 1 other active

    1 trial
  9. A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 1 other active

    1 trial
  10. A Phase I Randomized, Single-center, Double-blind, Two-period Crossover Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Icodec in Participants with Type 2 Diabetes.

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial
  11. A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumours

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumors

    phase 1 other active

    1 trial
  12. A Phase I study to evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

    Lacuna Pharma Pty Ltd

    Severe infections caused by Gram-negative bacteria

    phase 1 other active

    1 trial
  13. A Phase I trial to investigate the pharmacokinetics and ECG effects of single doses of linaprazan glurate administered as oral tablets to healthy participants

    Lacuna Pharma Pty Ltd

    Erosive Gastroesophageal Reflux Disease (eGERD)

    phase 1 other active

    1 trial
  14. A Phase I, open-label study in healthy adults comparing the availability in the body of the active substance lidocaine following administration of 2% and 4% lidocaine gel into the urethra

    Lacuna Pharma Pty Ltd

    bioavailability trial with healthy participants, therapeutic indication not studied

    phase 1 other active

    1 trial
  15. A Randomized Study in Healthy Participants to Identify the Optimal Subcutaneous Injection Strategy for COR-1167

    Lacuna Pharma Pty Ltd

    Chronic Heart Failure

    phase 1 other active

    1 trial
  16. A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia

    Lacuna Pharma Pty Ltd

    Schizophrenia

    phase 1 other active

    1 trial
  17. A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT DOSES OF ARM210 IN HEALTHY SUBJECTS.

    Lacuna Pharma Pty Ltd

    Cardiac arrhythmias

    phase 1 other active

    1 trial
  18. A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COR-1389

    Lacuna Pharma Pty Ltd

    Obesity / Right heart failure (healthy participants)

    phase 1 other active

    1 trial
  19. A Single Dose, Fast state, Crossover Replicate Bioequivalence Study of NITROFURANTOIN 100 mg prolonged-release capsules (IASIS PHARMA) vs.FURABID® 100 mg prolonged-release capsules (Amdipharm Limited)

    Lacuna Pharma Pty Ltd

    healthy subjects

    phase 1 other active

    1 trial
  20. A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants with Solid Cancers Treated with Cemiplimab

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumor

    phase 1 other active

    1 trial
  21. A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 1 other active

    1 trial
  22. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial
  23. A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers.

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-cell Malignancies

    phase 1 other active

    1 trial
  24. A Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Degludec and Insulin Icodec in Participants with Type 2 Diabetes

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources